Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$13.44 USD
-0.39 (-2.82%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $13.43 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DNLI 13.44 -0.39(-2.82%)
Will DNLI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DNLI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNLI
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review
DNLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Other News for DNLI
Denali Therapeutics' CMO Joins Royalty Pharma Board | DNLI Stock News
Royalty Pharma appoints Ho, Weatherman to board of directors
Denali noted no FDA panel meeting in call with William Blair
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License ...
Denali Therapeutics Inc (DNLI) Announces FDA Priority Review for Tividenofusp Alfa | DNLI stock news